|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001629,
umls-concept:C0006826,
umls-concept:C0007589,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0025148,
umls-concept:C0031727,
umls-concept:C0040132,
umls-concept:C0109317,
umls-concept:C0205195,
umls-concept:C0205615,
umls-concept:C0543431,
umls-concept:C0694890,
umls-concept:C0752312,
umls-concept:C0752313,
umls-concept:C1150579,
umls-concept:C1176289,
umls-concept:C1333340,
umls-concept:C1366882,
umls-concept:C1370600,
umls-concept:C1516119,
umls-concept:C1517132,
umls-concept:C1550278,
umls-concept:C1704259,
umls-concept:C1705767,
umls-concept:C1705791,
umls-concept:C1705987,
umls-concept:C1999216
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-8
|
|
pubmed:abstractText |
Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET) kinase pathways are important in thyroid cancer. We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP...,
http://linkedlifedata.com/resource/pubmed/chemical/Farnesyltranstransferase,
http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Protein p21(ras),
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-ret,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/RET protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/raf Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/sorafenib,
http://linkedlifedata.com/resource/pubmed/chemical/tipifarnib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1945-7197
|
|
pubmed:author |
pubmed-author:BidyasarSavitaS,
pubmed-author:BusaidyNaifa LNL,
pubmed-author:CabanillasMaria EME,
pubmed-author:El NaggarAdel KAK,
pubmed-author:El NaggarAlder KAK,
pubmed-author:HernandezMikeM,
pubmed-author:HongDavid SDS,
pubmed-author:KurzrockRazelleR,
pubmed-author:NaingAungA,
pubmed-author:ShermanSteven ISI,
pubmed-author:TsimberidouApostolia MAM,
pubmed-author:WaguespackSteven GSG,
pubmed-author:WhelerJenniferJ,
pubmed-author:WrightJohnJ,
pubmed-author:YeLeiL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
997-1005
|
|
pubmed:dateRevised |
2011-8-30
|
|
pubmed:meshHeading |
pubmed-meshheading:21289252-Adult,
pubmed-meshheading:21289252-Aged,
pubmed-meshheading:21289252-Aged, 80 and over,
pubmed-meshheading:21289252-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21289252-Benzenesulfonates,
pubmed-meshheading:21289252-Cell Differentiation,
pubmed-meshheading:21289252-Dose-Response Relationship, Drug,
pubmed-meshheading:21289252-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:21289252-Farnesyltranstransferase,
pubmed-meshheading:21289252-Female,
pubmed-meshheading:21289252-Humans,
pubmed-meshheading:21289252-MAP Kinase Kinase Kinases,
pubmed-meshheading:21289252-Male,
pubmed-meshheading:21289252-Middle Aged,
pubmed-meshheading:21289252-Oncogene Protein p21(ras),
pubmed-meshheading:21289252-Protein Kinase Inhibitors,
pubmed-meshheading:21289252-Proto-Oncogene Proteins c-ret,
pubmed-meshheading:21289252-Pyridines,
pubmed-meshheading:21289252-Quinolones,
pubmed-meshheading:21289252-Signal Transduction,
pubmed-meshheading:21289252-Thyroid Neoplasms,
pubmed-meshheading:21289252-raf Kinases
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
|
|
pubmed:affiliation |
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. dshong@mdanderson.org
|
|
pubmed:publicationType |
Journal Article
|
